NCT01455259View on ClinicalTrials.gov

Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

AdCD40L

Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.

Trial Locations (1)

75185

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Uppsala University Hospital

OTHER

lead

Uppsala University

OTHER

NCT01455259 - Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors | Biotech Hunter | Biotech Hunter